GlassScriptPhysician profile
Gaurav Jain
NPI 1851307680
$9,836.99
in general payments reported to CMS, 2019-2025
41 companies · $2,448 in 2025
The $2,448 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,543 · 2020: $501 · 2021: $722 · 2022: $737 · 2023: $1,933 · 2024: $1,953 · 2025: $2,448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,333.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,304.50 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,462.29 | 2019-2025 | Xifaxan, Plenvu, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $921.53 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $529.17 | 2021-2024 | Zeposia |
| Genzyme Corporation | $373.01 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $319.38 | 2019-2025 | Linzess |
| Madrigal Pharmaceuticals | $310.60 | 2025 | Rezdiffra |
| Pfizer INC. | $287.01 | 2019-2025 | |
| Janssen Biotech, INC. | $269.33 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Ardelyx, INC. | $251.93 | 2023-2025 | Ibsrela |
| Gilead Sciences, INC. | $210.08 | 2019-2025 | |
| Alphatec Spine, INC | $192.58 | 2019-2020 | |
| Lilly USA, LLC | $162.90 | 2024-2025 | Omvoh, Emgality |
| Regeneron Healthcare Solutions, INC. | $162.51 | 2023-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $141.99 | 2024-2025 | Voquezna |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $119.36 | 2024 | |
| Amgen INC. | $84.31 | 2025 | Uplizna |
| Qol Medical, LLC | $72.49 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $64.05 | 2020-2023 | Dificid |
| Globus Medical, INC. | $61.36 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.66 | 2023 | Cyltezo |
| Ipsen Biopharmaceuticals, INC | $48.08 | 2024-2025 | Iqirvo |
| Ferring Pharmaceuticals INC. | $45.68 | 2023 | Rebyota |
| Eisai INC. | $43.06 | 2019 | |
| Biofire Diagnostics, LLC | $37.68 | 2019 | |
| Shire North American Group INC | $31.43 | 2019 | |
| Aimmune Therapeutics, INC. | $28.47 | 2023 | |
| Intercept Pharmaceuticals, INC. | $25.00 | 2023 | Ocaliva |
| Allergan, INC. | $24.13 | 2019 | |
| Boston Scientific Corporation | $22.66 | 2019 | |
| Fresenius Kabi USA, LLC | $21.75 | 2023 | Idacio |
| Novo Nordisk INC | $21.09 | 2025 | Wegovy |
| Bioventus LLC | $20.81 | 2025 | Xcell |
| Alfasigma USA, INC. | $19.27 | 2020 | |
| Covidien LP | $16.06 | 2019 | |
| Sandoz INC. | $15.14 | 2024 | Hyrimoz |
| Amag Pharmaceuticals, INC. | $13.83 | 2019 | |
| Ebi, LLC | $13.74 | 2025 | Biomet Spinalpak Non-Invasive Spine Fusion Stimulator System |
| Redhill Biopharma INC. | $13.74 | 2020 | |
| Braintree Laboratories, INC. | $12.69 | 2023 | Suflave, Sutab |
| Dexcom, INC. | $11.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gaurav Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.